Media Interview and Presentation – Stockhead

Jun 30, 2021 | Webinars & Events

Hexima CEO, Michael Aldrige, spoke with Stockhead as part of their V-Con video conference series focused on biotechs. V-Con is Stockhead’s investing focused video conference series, bringing you expert insights, panel discussions and presentations from leading...

ShareCafe Webinar

May 21, 2021 | Webinars & Events

Hexima CEO, Michael Aldridge, presented at the ShareCafe Hidden Gems Webinar on 21 May 2021 at 12:30pm AEST. Mr Aldridge provided a company overview and discussed the strategic direction of Hexima, including the significance of the new INN designation and recognition...

R&D Investor Webinar

Mar 25, 2021 | Webinars & Events

Thank you to those that joined us for our first R&D Webinar. We had a great response and an engaged audience. For those that missed it, you can view the full recording via the link below. Topics covered on the day included: The strong science behind HXP124 and how...

Australian Financial Review: Niche products best option for biotechs

Dec 18, 2020 | Media

Hexima is pleased to be featured in the Australian Financial Review (AFR) article which highlights the often challenging path for Australian biotechs from clinical trails to commercialisation. CEO, Michael Aldrige, explains why he thinks Hexima is positioned well to...

Bioshares Number 873

Dec 14, 2020 | Media

Hexima CEO, Michael Aldridge, and Chief Operating Officer, Nicole van der Weerden, were recently interviewed by Bioshares. Michael and Nicole spoke to Bioshares about HXP124 and why it is well suited to onychomycosis, the encouraging efficacy results so far, our trial...